PMID- 23468981
OWN - NLM
STAT- MEDLINE
DCOM- 20130910
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 2
DP  - 2013
TI  - Multiple marker detection in peripheral blood for NSCLC diagnosis.
PG  - e57401
LID - 10.1371/journal.pone.0057401 [doi]
LID - e57401
AB  - BACKGROUND: Non-invasive early detection of lung cancer could reduce the number 
      of patients diagnosed with advanced disease, which is associated with a poor 
      prognosis. We analyzed the diagnostic accuracy of a panel of peripheral blood 
      markers in detecting non small cell lung cancer (NSCLC). METHODS: 100 healthy 
      donors and 100 patients with NSCLC were enrolled onto this study. Free 
      circulating DNA, circulating mRNA expression of peptidylarginine deiminase type 4 
      (PAD4/PADI4), pro-platelet basic protein (PPBP) and haptoglobin were evaluated 
      using a Real-Time PCR-based method. RESULTS: Free circulating DNA, PADI4, PPBP 
      and haptoglobin levels were significantly higher in NSCLC patients than in 
      healthy donors (p<0.0001, p<0.0001, p=0.0002 and p=0.0001, respectively). The 
      fitted logistic regression model demonstrated a significant direct association 
      between marker expression and lung cancer risk. The odds ratios of individual 
      markers were 6.93 (95% CI 4.15-11.58; p<0.0001) for free DNA, 6.99 (95% CI 
      3.75-13.03; p<0.0001) for PADI4, 2.85 (95% CI 1.71-4.75; p<0.0001) for PPBP and 
      1.16 (95% CI 1.01-1.33; p=0.031) for haptoglobin. Free DNA in combination with 
      PPBP and PADI4 gave an area under the ROC curve of 0.93, 95% CI=0.90-0.97, with 
      sensitivity and specificity over 90%. CONCLUSIONS: Free circulating DNA analysis 
      combined with PPBP and PADI4 expression determination appears to accurately 
      discriminate between healthy donors and NSCLC patients. This non-invasive 
      multimarker approach warrants further research to assess its potential role in 
      the diagnostic or screening workup of subjects with suspected lung cancer.
FAU - Ulivi, Paola
AU  - Ulivi P
AD  - Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la 
      Cura dei Tumori, Meldola, Italy. p.ulivi@irst.emr.it
FAU - Mercatali, Laura
AU  - Mercatali L
FAU - Casoni, Gian-Luca
AU  - Casoni GL
FAU - Scarpi, Emanuela
AU  - Scarpi E
FAU - Bucchi, Lauro
AU  - Bucchi L
FAU - Silvestrini, Rosella
AU  - Silvestrini R
FAU - Sanna, Stefano
AU  - Sanna S
FAU - Monteverde, Marco
AU  - Monteverde M
FAU - Amadori, Dino
AU  - Amadori D
FAU - Poletti, Venerino
AU  - Poletti V
FAU - Zoli, Wainer
AU  - Zoli W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130226
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Carcinoma, Non-Small-Cell Lung/*blood
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*blood
MH  - Male
MH  - Middle Aged
MH  - Real-Time Polymerase Chain Reaction
PMC - PMC3582604
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2013/03/08 06:00
MHDA- 2013/09/11 06:00
PMCR- 2013/02/26
CRDT- 2013/03/08 06:00
PHST- 2012/11/05 00:00 [received]
PHST- 2013/01/21 00:00 [accepted]
PHST- 2013/03/08 06:00 [entrez]
PHST- 2013/03/08 06:00 [pubmed]
PHST- 2013/09/11 06:00 [medline]
PHST- 2013/02/26 00:00 [pmc-release]
AID - PONE-D-12-34055 [pii]
AID - 10.1371/journal.pone.0057401 [doi]
PST - ppublish
SO  - PLoS One. 2013;8(2):e57401. doi: 10.1371/journal.pone.0057401. Epub 2013 Feb 26.